

FIG. 1

Reduction in HSV1 infectivity after treatment with various concentrations of apoE derived peptides




FIG. 2

Reduction in HSV2 infectivity after treatment with various concentrations of apoE derived peptides




FIG. 3

Reduction in HIV infectivity after treatment with various concentrations of apoE derived peptides




FIG. 4

Reduction in HSV1 infectivity after treatment with various concentrations of apolipoprotein derived peptides




FIG 5

Reduction in HSV1 infectivity after treatment with various concentrations of apoB derived peptides




FIG 6

Reduction in HIV infectivity after treatment of NP2 glioma cells with various concentrations of apoB derived GIN 33, or apoE- derived apoE141-149.





FIG 7

FIG 8